(0.23%) 5 111.65 points
(0.23%) 38 328 points
(0.21%) 15 961 points
(-1.38%) $82.69
(4.26%) $2.01
(-0.04%) $2 346.30
(-0.12%) $27.50
(3.68%) $956.00
(-0.15%) $0.933
(-0.24%) $11.00
(-0.45%) $0.797
(1.75%) $93.48
@ $11.29
发出时间: 14 Feb 2024 @ 04:33
回报率: -10.54%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 2.98 %
Live Chart Being Loaded With Signals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...
Stats | |
---|---|
今日成交量 | 52 483.00 |
平均成交量 | 430 561 |
市值 | 1.04B |
EPS | $0 ( 2024-03-19 ) |
下一个收益日期 | ( $-0.740 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.89 |
ATR14 | $0.0180 (0.18%) |
音量 相关性
Immatics N.V. 相关性 - 货币/商品
Immatics N.V. 财务报表
Annual | 2023 |
营收: | $54.00M |
毛利润: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2023 |
营收: | $54.00M |
毛利润: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2022 |
营收: | $172.83M |
毛利润: | $66.05M (38.22 %) |
EPS: | $0.550 |
Financial Reports:
No articles found.
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。